8 September 2022

ValiRx PLC ("ValiRx" or the "Company")

Appointment of Interim Chief Scientific Officer

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to announce the appointment of Dr Catherine ("Cathy") Tralau-Stewart as interim Chief Scientific Officer (a non-board position).

Dr Tralau-Stewart has experience working across leading pharmaceutical companies and academic groups, with a particular focus on the interaction between industry and academia.  Her role within the Company will encompass the review of new, incoming science; enhancing the progress of existing projects; and influencing the overall strategic scientific direction of the Company.

Dr Suzy Dilly, CEO of ValiRx PLC commented "I'm delighted to have the opportunity to work with Cathy, I'm looking forward to having another in-house scientist with whom to share ideas and to develop and deliver upon our strategic ambitions.  Cathy's wealth of experience in exactly the areas in which we wish to progress, makes her an excellent choice for this role."

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.